Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin
This article was originally published in The Pink Sheet Daily
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.
You may also be interested in...
The Indiana-based big pharma will focus on product-level acquisitions in its core areas of strengths now that it has rounded out its animal health business with its $5.4 billion acquisition of Novartis Animal Health.
The three new medicines tackle ulcerative colitis and Crohn’s disease, diabetes and ovarian cancer, respectively, with final approval from the European Commission expected in around two months.
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.